RESOURCES (BACKUP COPY)

During the past few years, scientific journals have published an increasing number of groundbreaking articles about the efficacy of employing T-cell bispecific antibodies (TRBAs) in cancer immunotherapy. The research is encouraging: More than 50 bispecific antibodies are currently in clinical trials. Below are links to recent scholarship and resources that can help practices better serve their patients who may be eligible for TRBA therapy, including education materials and information about financial resources.